These papers were presented on the 3rd International Conference on Biology and Mushroom Products held at Oct. 1999.in Sydney, Australia.

第3回 国際生物学・キノコ会議にて発表
於:1999年10月オーストラリア・シドニー

Maitake (Grifola frondosa) can maintain the Health of People suffering with BIV infection?
Maitake Glucan (MD-Fraction ) can stop the cancer growth?

Maitake (Grifola frondosa) can maintain the Health of People suffering with BIV infection?
A. マイタケMD-フラクションは、エイズ患者の苦しみを緩和

Hiroaki Nanba ph. D.,Noriko Kodama ph. D. …@
Doglas Schar and Denise Turner ph. D.…A
@ Department of Microbial Chemistry, Kobe Pharmaceutical University, 4-19-1,
  Motoyamakita-machi,Higashinada-ku, kobe 658-8558, Japan
AHerbal Clinical Research, Columbia Road, London, U. K.
発表者:難波宏彰 神戸薬科大学教授、デニス・タナー 英国

ABSTRACT
We had reported that Maitake glucan named MD-Fraction can show a regression by activation of not only immune-competent cells but productions of cytokine.Especially, MD-Fraction potentiates the activity of helper T cells (Th: one subset of CD4' cell) which acts as a regulator of immune-system. But it is well-known that one is the main target cell of HIV. If MD-Fraction indicates the activation of HN-infected Th, we have a chance to cure the HIV positive-patients.

Therefore, we tried the long trial to evaluate the effect of Maitake on the maintenance of health condition of HIV-infected patients. 25 patients in England and 10 respondents in U. S. A. were administered the tablets containing 3-6 g Maitake powder with 5-10 mg vitamin C continuously for one year. And we embarked and followed up at monthly intervals in order to monitor the HIV states reflected by CD4' cell counts. Also, measure of Viral load and concomitant conditions by HIV infection were studied. We could observe that CD4' cells increased to 1.2-1.83 times in 20 patients and indicated in 7 patients a non-change of total cell counts.

But, also the decrease of this cell was showed in 8 patients. Viral load count report was as follows, decreased to 0.9-0.7 times in l0patients, increased to 1.3-1.9 times in 9 patients, and was statical in 16 patients. Also, concomitant conditions were cured in 80% patients. Especially 89.7% of Candida-infection disease and 75% of Kapos;-Sarcoma were disappeared. These results suggest that Maitake indicates positive action for HIV infected-patients.

These papers were presented on the 3'd International Conference on Biology and Mushroom Products held at Oct. 1999.in Sydney, Australia.

TOP BACK



第3回 国際生物学・キノコ会議にて発表
於:1999年10月オーストラリア・シドニー

Maitake Glucan (MD-Fraction ) can stop the cancer growth?
B. マイタケMD-フラクションは、がん細胞の増殖を抑制


Noriko Kodama ph. D. @、Kiyoshi Komuta M. D. ph. D. A、and Hiroaki Nanba ph. D. @
@Departrnent of Microbial Chemistry, Kobe Pharmaceutical University, 4-19-1,
Motoyamakita-machi, Higashinada-ku, kobe 658-8558, Japan
AOsaka Police Hospital, Kitayama-cho, Tennouji-ku , Osaka
発表:@児玉典子、難波宏彰 神戸薬科大学 A小牟田清 大阪警察病院

ABSTRACT
Beta i, 6-glucan having beta 1, 3-side chain named MD-Fraction in edible Maitake mushroom (Grifola frondosa) indicates an ability to potentiate and activate the cellular immune-competent cells, such as helper T cell, cytotoxic T cell, delayed-type hypersensitive T cell, natural killer cell and macrophage.
Also, the productions of various kinds of cytokines, such as Interleukin-l (IL-1), 1L-2 , and interferon, which can adtivate these immune-competent cells increased to 1.7-3.4 times. When these immune systems were increased by oral or i. p. administration of Maitake, a growth of breast cancer (MM 46 carcinoma), Lung cancer (Lewis Lung carcinoma), and liver cancer (MH-164 carcinoma) were inhibited to 75-91% in animal test.

Then, we tried a non-randomized clinical study by addition of 100-250 mg/day MD-Fraction with tablets containing 3-6 g Maitake powder and 5-10 mg vitamin C for 72 cancer- patients in stage III-TV between 33-68 years old during one year. Cancer regressions and improvements ofcancer-immune response were observed in 64% in Lung cancer patients, in 70% in breast cancer patients, and in 60% in liver cancer patients.
By addition of Maitake-components with chemotherapy together, these regression- rates of cancer were improved and indicated that 70-83% of patients were cured. Both of immune-competent cell activities and production of cytokine (Interleukin-2) were enhanced to 1.25-2.7 times, respectively. These results indicate that these all actions inhibit the cancer-growth. We try more clinical studies, but this small trial results suggest that we have a possibility of survival of cancer disease by Maitake.  



 TOP BACK